SBK Secures in Series B Funding to Advance Metabolic Differentiation and Drive Innovation in Cardiovascular and Respiratory Therapies

Chengdu Shibeikang Biomedical Technology Co., Ltd. (SBK) has announced the successful completion of Series B funding round led exclusively by strategic investor Chengda Pharmaceutical, a publicly listed company. The funding will be used to accelerate the development of SBK’s R&D pipeline, expand its laboratory facilities, and advance the international registration of its core products. In its early growth stage, SBK also attracted investments from leading industry players, including Fosun Pharma, Sichuan Venture Capital and several local investment institutions.

Founded in 2015, SBK is a research-driven company rooted in China, serving the world and dedicated to differentiated drug innovation. Guided by a dual drivers of “addressing clinical urgency” and “global innovation”, the company focuses on therapeutic areas including cardiovascular and respiratory diseases. Through its proprietary AI-powered metabolic differentiation platform, SBK has established a fully integrated drug development system spanning the entire R&D value chain.

SBK’s R&D team possesses full-chain independent development capabilities spanning bioinformatics, structural design, CMC, pharmacological and toxicological research, patent studies, clinical research, and regulatory submissions. The team was recognized as a top innovation and entrepreneurship team under Chengdu’s “Rong Piao Plan” in 2021 and as part of the “Tianfu Emei Plan” in 2022. With 32% of its members holding master’s or doctoral degrees and an average of more than 20 years of experience in drug R&D and management, the team brings deep expertise and proven leadership to the company’s innovation efforts.

Powered by the AI Metabolic Platform: Building a More Efficient R&D System

In the complex and lengthy process of innovative drug development, challenges such as unclear metabolic properties and low clinical translation rates remain common. SBK’s core strength lies in its proprietary A-MetaForge™ AI metabolic differentiation platform, which drives its competitive edge in overcoming these hurdles.

By combining cross-species metabolic data with advanced AI algorithms, the platform enables precise, differentiated analysis of drug metabolic properties, uncovering insights often missed by traditional models. Its multi-dimensional modeling capability precisely identifies clinical metabolic risks and structural optimization opportunities. This significantly enhances R&D efficiency and success rates from early discovery through clinical translation, accelerating the delivery of innovative therapies to address unmet medical needs.

Leveraging this platform, SBK has strategically advanced multiple innovative pipelines in the fields of cardiovascular and respiratory diseases, with several candidates already progressing through various clinical stages.

Driven by Capital and Industry Synergy: Building a Strategic R&D and Manufacturing Alliance

This funding round extends beyond capital investment, and also marks a deep integration of strategic resources between the two parties.

As a company operating to international standards in pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and CDMO services, Chengda Pharmaceutical brings a well-established global quality system and strong compliance capabilities. Complementing this, SBK’s differentiated R&D pipelines and cutting-edge technology provide distinct strengths in early-stage drug discovery and clinical development.

Through this collaboration, Chengda Pharmaceutical’ extensive expertise in API development, GMP manufacturing, and international regulatory registration will provide comprehensive support for SBK’s efforts to advance multiple product pipelines globally, accelerating their path to international markets. Chengda Pharmaceutical will provide a stable, compliant, and efficient supply of APIs and intermediates for SBK’s innovative drug pipeline through advanced production technologies, a robust international quality system, and high-value development capabilities. This partnership safeguards drug quality from the source, ensuring adherence to global standards throughout all clinical and commercial stages. Additionally, Chengda Pharmaceutical’ deep experience in international regulatory registration and GMP compliance will play a crucial role in supporting the market entry of SBK’s products in major pharmaceutical markets such as the United States and Europe, effectively mitigating registration risks and expediting the approval process.

By organically combining capital and industry expertise, the two parties will establish a strategic “R&D + Manufacturing + Global Expansion” alliance, enabling end-to-end collaboration from early-stage research through to commercial production.

Moving forward, SBK’s near-term priority is the efficient advancement of its clinical-stage pipeline. The company aims to rapidly bring its innovative drugs to market, each developed through a metabolic differentiation strategy with clearly demonstrated efficacy and safety. Over the long term, the company plans to deepen its integrated “Prevention–Diagnosis–Treatment” approach, build a comprehensive cardiovascular and cerebrovascular ecosystem, continuously strengthen its foundational innovation capabilities, and ultimately develop First-in-Class therapies with global patent protection and out-licensing potential.

Commenting on this funding round, Tan Shaojun, Founder and Chairman of SBK, said: “We sincerely appreciate the recognition and trust of our investors. This funding represents a pivotal step as we move toward global commercialization. Chengda Pharmaceutical not only brings world-class CDMO capabilities that align perfectly with our internationalization strategy, but also provides systematic support to help us overcome production and supply chain challenges in bringing our products to the global market. Furthermore, their financial backing will significantly strengthen our R&D efforts, allowing us to deepen innovation in areas such as cardiovascular and respiratory diseases. We remain committed to delivering clinical value and accelerating the availability of globally competitive, innovative therapies to benefit patients as soon as possible.”

Chengda Pharmaceutical commented: “With its world-leading metabolic differentiation R&D platform and comprehensive clinical translation capabilities, SBK has achieved remarkable progress in efficiently advancing multiple new drugs. We look forward to collaborating with SBK to drive innovative drug development, strengthen its product pipeline, expand clinical applications, and advance its global strategy. Through this partnership, we are committed to fully supporting SBK’s growth and jointly creating greater value for global healthcare.”